Covington, Skadden Steer Merck's $2.7B Deal For ArQule
Merck & Co. continued a 2019 buying spree Monday with the roughly $2.7 billion acquisition of cancer-focused biotech ArQule Inc., in a deal put together with help from Covington and Skadden....To view the full article, register now.
Already a subscriber? Click here to view full article